

New York State Department of Health Bureau of Immunization

COVID-19 Vaccine Screening and Consent Form

Rec	ipient Name (please print)	Preferred Name				
Add	ress City	State Zip	Email Address			
Par	ent/Guardian/Surrogate (if applicable, please print)	Phone	Preferred Language			
DO	OB Current Gender ID Key: W – Woman/Girl TW – Transgender Woman/Girl M – Man/Boy Indicate ID Below: TM – Transgender Man/Boy NB – Non-Binary Person GNC – Gender Non-Conform Q – Not Sure/Questioning NR – Chose not to Respond GNL - Gender not Listed (write-in) * Gender Pronouns: write-in by client's name					
	Assigned at Birth Key: cate Sex Below: M – Male F – Female I – Intersex NR – Chose not to Respond	Marital Status Key: S – Single D – Divorced M – Married Indicate Status Below: W – Widowed V – Civil Union U – Unknown SEPARATED – Legally Separated PARTNER – Life Partner				
	nicity Key: DECL – Declined cate Ethnicity Below: HIS – Hispanic Origin NHL – Non-Hispanic Origin UNK – Unknown	Indicate Race Below: BAA – NHP –	Native American or Alaskan ASN – Asian - African American or Black DECL – Declined - Native Hawaiian or Pacific Islander – White OTH – Other or Multiracial			
Prir	nary Insurance Name	Primary Insurance ID#	Subscriber N	ame/DOB	Subscriber Relation to Patient	
Prir	nary Insurance Address	Primary Insurance Group #	Primary Insurance Phone #			
Secondary Insurance Name		Secondary Insurance ID#	Subscriber Name/DOB Subscriber to Patient		Subscriber Relation to Patient	
Secondary Insurance Address		Secondary Insurance Group # Secondary Insurance Phone #			one#	
Clin	ic/Office Site Where Vaccine is Administered	Primary Care Physician Address	/Phone Numbe	er		
		Screening Questionnaire				
1.	Are you feeling sick today?		□ Yes	□ No	□ Unknown	
2.	□ No	□ Unknown				
3.	Have you been treated with antibody therapy or on the past 90 days (3 months)? If yes, when did you	9 🗆 Yes	□ No	□ Unknown		
4.	Have you ever had an immediate allergic reaction difficulty breathing, anaphylaxis) to any vaccine, ir component of the COVID-19 vaccine, or a severe anything?	□ Yes	□ No	□ Unknown		
5.	Are you pregnant or considering becoming pregna	ant?	□ Yes	□ No	□ Unknown	
6.	Do you have cancer, leukemia, HIV/AIDS or any ot immune system?		□ Yes	□ No	□ Unknown	
7.	Do you take any medications that affect your imm prednisone or other steroids, anticancer drugs, or treatments?	, , , , , , , , , , , , , , , , , , , ,			□ Unknown	
8.	Do you have a bleeding disorder, a history of bloo thinner?	d clots or are you taking a blood	□ Yes	□ No	□ Unknown	

o you have a history of myocarditis (inflammation of the heart muscle) or		□ No	□ Unknown
pericarditis (inflammation of the lining around the heart)?			
lave you had Guillain-Barre Syndrome after receipt of the Janssen vaccine?	□ Yes	□ No	□ Unknown
Do you have a history of MIS-C or MIS-A (multisystem inflammatory syndrome in	□ Yes	□ No	□ Unknown
hildren or multisystem inflammatory syndrome in adults)?			
Are you 12 years of age or older and have you received a complete COVID-19 vaccine	□ Yes	□ No	
orimary series (e.g., 2 doses of Moderna, Pfizer, or Novavax vaccine, or 1 dose of			
anssen vaccine) or any booster dose at least 2 months ago?			Date of last dose:
			(if applicable)
f you had a previous dose of Janssen (Johnson & Johnson), did you develop	□ Yes	□ No	□ Unknown
hrombosis with thrombocytopenia syndrome (TTS)?			
Have you received a previous dose of a non-FDA authorized or approved COVID-19	□ Yes	□ No	□ Unknown
raccine authorized by the WHO ¹ but not by the FDA (AstraZeneca – VAXZEVRIA,			
inovac – CORONAVAC, Serum Institute of India – COVISHIELD, Sinopharm/BIBP,			
COVAXIN, Nuvaxovid, COVOVAX, or CanSino Biologics – Convidecia)?			
H O H O H Va ii	ave you had Guillain-Barre Syndrome after receipt of the Janssen vaccine? To you have a history of MIS-C or MIS-A (multisystem inflammatory syndrome in hildren or multisystem inflammatory syndrome in adults)? The you 12 years of age or older and have you received a complete COVID-19 vaccine rimary series (e.g., 2 doses of Moderna, Pfizer, or Novavax vaccine, or 1 dose of anssen vaccine) or any booster dose at least 2 months ago? Tyou had a previous dose of Janssen (Johnson & Johnson), did you develop perombosis with thrombocytopenia syndrome (TTS)? Tave you received a previous dose of a non-FDA authorized or approved COVID-19 accine authorized by the WHO¹ but not by the FDA (AstraZeneca – VAXZEVRIA, inovac – CORONAVAC, Serum Institute of India – COVISHIELD, Sinopharm/BIBP,	ave you had Guillain-Barre Syndrome after receipt of the Janssen vaccine? o you have a history of MIS-C or MIS-A (multisystem inflammatory syndrome in hildren or multisystem inflammatory syndrome in adults)? re you 12 years of age or older and have you received a complete COVID-19 vaccine rimary series (e.g., 2 doses of Moderna, Pfizer, or Novavax vaccine, or 1 dose of anssen vaccine) or any booster dose at least 2 months ago? Tyou had a previous dose of Janssen (Johnson & Johnson), did you develop or or on the promotories with thrombocytopenia syndrome (TTS)? Lave you received a previous dose of a non-FDA authorized or approved COVID-19 accine authorized by the WHO¹ but not by the FDA (AstraZeneca – VAXZEVRIA, inovac – CORONAVAC, Serum Institute of India – COVISHIELD, Sinopharm/BIBP,	ave you had Guillain-Barre Syndrome after receipt of the Janssen vaccine? O you have a history of MIS-C or MIS-A (multisystem inflammatory syndrome in hildren or multisystem inflammatory syndrome in adults)? The you 12 years of age or older and have you received a complete COVID-19 vaccine or imary series (e.g., 2 doses of Moderna, Pfizer, or Novavax vaccine, or 1 dose of enssen vaccine) or any booster dose at least 2 months ago? The you had a previous dose of Janssen (Johnson & Johnson), did you develop or or one with thrombocytopenia syndrome (TTS)? The you received a previous dose of a non-FDA authorized or approved COVID-19 or yes or none authorized by the WHO¹ but not by the FDA (AstraZeneca – VAXZEVRIA, inovac – CORONAVAC, Serum Institute of India – COVISHIELD, Sinopharm/BIBP,

^{*}Question #12 pertain to monovalent/bivalent booster dose eligibility for Pfizer, Moderna, Novavax or Janssen.

Emergency Use Authorization

The FDA has made the COVID-19 vaccine available under an emergency use authorization (EUA). The EUA is used when circumstances exist to justify the emergency use of drugs and biological products during an emergency, such as the COVID-19 pandemic. This vaccine has not undergone the same type of review as an FDA-approved or cleared product. However, the FDA's decision to make the vaccine available is based on the totality of scientific evidence available, showing that known and potential benefits of the vaccine outweigh the known and potential risks. The Janssen (Johnson & Johnson) COVID-19 vaccine is EUA authorized for those individuals 18 years old and older. The Novavax COVID-19 vaccine is EUA authorized for those individuals 12 years and older. Please note: FDA approved the Pfizer-BioNTech COVID-19 vaccine as a two-dose series in individuals 16 years of age and older; and approved the Moderna COVID-19 vaccine as a two-dose series in individuals 18 years of age and older. These vaccines continue to be available under an EUA for certain populations, including Pfizer-BioNTech COVID-19 vaccine for those individuals 6 months through 15 years old, and Moderna COVID-19 vaccine for individuals 6 months through 17 years old and for the administration of a third dose in the populations set forth in the consent section below.

Emergency Use Instruction

Emergency Use Instructions (EUIs) are issued by the CDC to provide information about emergency use of FDA-approved medical products that may not be included in or differ in some way from the information provided in the FDA-approved labeling (package insert). The COVID-19 vaccine by Pfizer-BioNTech is an FDA-approved COVID-19 vaccine (brand name Comirnaty, mRNA) to prevent COVID-19 in persons 12 years of age and older. CDC is issuing EUI to provide information about use of this vaccine as an additional primary dose in certain immunocompromised persons (12 years of age and older) and a booster dose in certain adults (18 years of age and older) who received certain non-FDA authorized or approved COVID-19 vaccine (e.g., certain vaccines available outside of the United States or from clinical trial participation).

^{**}Question #13 pertains to booster dose eligibility for Janssen.

¹ As set forth in the CDC's Emergency Use Instructions (EUI), a non-FDA authorized or approved COVID-19 vaccine such as those vaccines "listed for emergency use by the World Health Organization, or is included in CDC's Technical Instructions for Implementing Presidential Proclamation Advancing Safe Resumption of Global Travel During the COVID-19 Pandemic and CDC's Order, or that is a non-placebo part of a clinical trial within or outside the United States that is a WHO-EUL COVID-19 vaccine or a vaccine that is not listed for emergency use by WHO but for which a U.S. data and safety monitoring board or equivalent has independently confirmed efficacy in the United States (hereinafter "non-FDA authorized or approved COVID-19 vaccines").

Consent

I have read, or had explained to me, the information sheet about the COVID-19 vaccination. I understand that if my vaccine requires two doses, I will need to be administered (given) two doses to be considered fully vaccinated. Further, I understand that a booster dose of COVID-19 vaccine is recommended at least 2 months following the first dose of Janssen vaccine (if I am age 18 or older), or at least 5 months following the second dose of Pfizer-BioNTech (if I am age 5 -11 years old) or at least 2 months following my most recent vaccine if I am 12 years old or older (Pfizer-BioNTech or Moderna COVID-19 vaccine) to increase my protection.

I have had a chance to ask questions which were answered to my satisfaction (and ensured the person named above for whom I am authorized to provide surrogate consent was also given a chance to ask questions). I understand the benefits and risks of the vaccination as described.

I request that the COVID-19 vaccination be given to me (or the person named above for whom I am authorized to make this request and provide surrogate consent). I understand there will be no cost to me for this vaccine. I understand that any monies or benefits for administering the vaccine will be assigned and transferred to the vaccinating provider, including benefits/monies from my health plan, Medicare or other third parties who are financially responsible for my medical care. I authorize release of all information needed (including but not limited to medical records, copies of claims and itemized bills) to verify payment and as needed for other public health purposes, including reporting to applicable vaccine registries.

Recipient/Surrogate/Guardian (Signature) Date / Time	Print Name	Relationship to Patient (if other than recipient)					
Telephonic Interpreter's ID # Date / Time							
OR							
OR							
Signature: Interpreter Date/ Time Print: Interpreter's Name and Relationship to Patient							

Area Below to be Completed by Vaccinator							
Which vaccine is the patient receiving today?							
Vaccine Name		Admi	nistration		Manufacturer & Lot #	EUA Fact Sheet Date	
Pfizer/BioNTech	□ First Dose	□ Second Dose	□ Bivalent Booster (≥ 12 years old)				
Moderna	□ First Dose	☐ Second Dose	☐ Bivalent Booster (≥ 18 years old)				
Novavax	□ First Dose	□ Second Dose	□ Bivalent mRNABooster(≥ 18 years old)				
Janssen	☐ Single Dose	□ Additional Dose	☐ Bivalent mRNA Booster (≥ 18 years old)				
Administration Site	□ Left Deltoid	□ Right Deltoid	□ Left Thigh	□ Right Thigh			
Dosage	□ 0.5 ml	□ 0.3 ml	□ 0.25 ml				

Site					
Dosage	□ 0.5 ml	□ 0.3 ml	□ 0.25 ml		
•	sent to vaccina	tient (and/or par ation was obtaine		ırrogate, as ap	plicable) with information about the
* Use of this fo	rm is optional				Updated September 13. 20